NovoCure (NVCR) Revenue (2014 - 2026)

NovoCure (NVCR) has reported Revenue for 13 consecutive years, with $183.6 million the latest figure, recorded in Q2 2026.

• Quarterly Revenue rose 15.6% year-over-year to $183.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $699.2 million (up 10.95% YoY) and the FY2025 annual result came in at $655.4 million, up 8.28% from the prior year.
• Revenue grew to $183.6 million in Q2 2026 per NVCR's latest filing, from $174.1 million in the prior quarter.
• Over the last five years, Revenue for NVCR reached as high as $183.6 million in Q2 2026 and fell as low as $122.2 million in Q1 2023.
• A 5-year average of $148.1 million and a median of $145.6 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue dropped 11.17% — and 2024, when it increased 21.81%.
• Year by year, Revenue stood at $128.4 million in 2022, then gained by 4.17% to $133.8 million in 2023, then increased by 20.54% to $161.3 million in 2024, then climbed by 8.11% to $174.4 million in 2025, then increased by 5.3% to $183.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $183.6 million, $174.1 million, and $174.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.